134 related articles for article (PubMed ID: 30249872)
1. The clinical importance of serum galectin-3 levels in breast cancer patients with and without metastasis.
Topcu TO; Kavgaci H; Gunaldi M; Kocoglu H; Akyol M; Mentese A; Yaman SO; Orem A; Ozdemir F; Aydin F
J Cancer Res Ther; 2018 Sep; 14(Supplement):S583-S586. PubMed ID: 30249872
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
[TBL] [Abstract][Full Text] [Related]
4. Serum galectin 3, galectin 9 and galectin 3-binding proteins in patients with active and inactive inflammatory bowel disease.
Cibor D; Szczeklik K; Brzozowski B; Mach T; Owczarek D
J Physiol Pharmacol; 2019 Feb; 70(1):. PubMed ID: 31019124
[TBL] [Abstract][Full Text] [Related]
5. Serum galectin-3 as a potential marker for gastric cancer.
Cheng D; Liang B; Li Y
Med Sci Monit; 2015 Mar; 21():755-60. PubMed ID: 25765552
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke.
He XW; Li WL; Li C; Liu P; Shen YG; Zhu M; Jin XP
Sci Rep; 2017 Jan; 7():40994. PubMed ID: 28112232
[TBL] [Abstract][Full Text] [Related]
7. Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity.
Lee YJ; Kang SW; Song JK; Park JJ; Bae YD; Lee EY; Lee EB; Song YW
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S41-5. PubMed ID: 17949550
[TBL] [Abstract][Full Text] [Related]
8. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
9. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
10. Potential value of circulatory microRNA10b gene expression and its target E-cadherin as a prognostic and metastatic prediction marker for breast cancer.
Dwedar FI; Shams-Eldin RS; Nayer Mohamed S; Mohammed AF; Gomaa SH
J Clin Lab Anal; 2021 Aug; 35(8):e23887. PubMed ID: 34264524
[TBL] [Abstract][Full Text] [Related]
11. Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors.
Išić T; Savin S; Cvejić D; Marečko I; Tatić S; Havelka M; Paunović I
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1805-12. PubMed ID: 20204403
[TBL] [Abstract][Full Text] [Related]
12. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer.
Zhang K; Luo Z; Zhang Y; Zhang L; Wu L; Liu L; Yang J; Song X; Liu J
Cancer Biomark; 2016 Jun; 17(2):187-94. PubMed ID: 27540977
[TBL] [Abstract][Full Text] [Related]
13. 8-Hydroxy-2'-deoxyguanosine as a Discriminatory Biomarker for Early Detection of Breast Cancer.
Nour Eldin EEM; El-Readi MZ; Nour Eldein MM; Alfalki AA; Althubiti MA; Mohamed Kamel HF; Eid SY; Al-Amodi HS; Mirza AA
Clin Breast Cancer; 2019 Apr; 19(2):e385-e393. PubMed ID: 30683611
[TBL] [Abstract][Full Text] [Related]
14. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
[TBL] [Abstract][Full Text] [Related]
15. Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer.
Zuo X; Chen L; Liu L; Zhang Z; Zhang X; Yu Q; Feng L; Zhao X; Qin T
Tumour Biol; 2016 Jan; 37(1):1309-17. PubMed ID: 26289852
[TBL] [Abstract][Full Text] [Related]
16. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.
Elfagieh M; Abdalla F; Gliwan A; Boder J; Nichols W; Buhmeida A
Tumour Biol; 2012 Dec; 33(6):2371-7. PubMed ID: 22948780
[TBL] [Abstract][Full Text] [Related]
17. Circulating and tissue galectin-1 and galectin-3 in colorectal carcinoma: association with clinicopathological parameters, serum CEA, IL-17 and IL23.
Petrovic S; Radosavljevic GD; Pantic J; Jovanovic I; Jankovic N; Arsenijevic N
J BUON; 2016; 21(4):941-949. PubMed ID: 27685917
[TBL] [Abstract][Full Text] [Related]
18. The utility of serum tumor markers CEA and CA 15-3 for breast cancer prognosis and their association with clinicopathological parameters.
Uygur MM; Gümüş M
Cancer Treat Res Commun; 2021; 28():100402. PubMed ID: 34082362
[TBL] [Abstract][Full Text] [Related]
19. Circulating neuregulin-1 and galectin-3 can be prognostic markers in breast cancer.
De Iuliis F; Salerno G; Taglieri L; Lanza R; Cardelli P; Scarpa S
Int J Biol Markers; 2017 Jul; 32(3):e333-e336. PubMed ID: 28430337
[TBL] [Abstract][Full Text] [Related]
20. The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer.
Hebbar M; Révillion F; Louchez MM; Vilain MO; Fournier C; Bonneterre J; Peyrat JP
Clin Cancer Res; 1998 Feb; 4(2):373-80. PubMed ID: 9516925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
